Rare diseases
Investigational molecules
Locations
705 conditions with trials, the busiest first
3 901 trials across Europe, recruiting first
Study of Pembrolizumab and Chemotherapy for Patients with HR+/HER2- Advanced Breast Cancer
AustriaStudy of Pembrolizumab and Axitinib Combination Versus Sunitinib for Patients with Advanced or Metastatic Kidney Cancer
CzechiaStudy on the Safety and Tolerability of TransCon IL-2 β/γ, Pembrolizumab, and Chemotherapy in Adults with Advanced or Metastatic Solid Tumors
BelgiumStudy of RVU120 for Patients with Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia
FranceStudy of Vobramitamab Duocarmazine and Prednisone for Patients with Metastatic Castration-Resistant Prostate Cancer
BelgiumStudy of Pembrolizumab and BCG for Patients with High-Risk Non-Muscle Invasive Bladder Cancer
AustriaStudy on Trilaciclib and Topotecan for Patients with Extensive Stage Small Cell Lung Cancer
AustriaOpen‑Label Extension Study of Avutometinib Alone or with Defactinib in Patients with Recurrent Low‑Grade Serous Ovarian Cancer
FranceStudy of Atezolizumab with Lenvatinib or Sorafenib vs Lenvatinib or Sorafenib alone in Unresectable Hepatocellular Carcinoma after Atezolizumab and Bevacizumab
AustriaDurvalumab versus standard chemotherapy drug combination in elderly patients with advanced non‑small cell lung cancer
ItalyStudy of denikitug alone or in drug combination in adults with advanced microsatellite stable colorectal cancer
FranceContinuation study of JDQ443 in patients with KRAS G12C‑mutated non‑small cell lung cancer receiving JDQ443 as monotherapy or drug combination
BelgiumThe therapies tested most often in Neoplasms benign, malignant and unspecified (incl cysts and polyps) trials.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
